Skip to main content

Table 2 Clinical characteristics of the patients with pseudolithiasis

From: Ceftriaxone-associated pseudolithiasis in hemodialysis patients: a case series study

Patient Abdominal symptoms Abnormalities in levels of transaminases/biliary enzymes Dose of CTRX [g/day × duration (days)] Dose of CTRX (mg/kg/day) aDays to development bDays to disappearance Site Treatment
1 −/− 2 × 13 60.6 15 c GB
2 +/− 1 × 14 21.5 27 319 GB
3 Vomiting +/− 1 × 14 21.6 35 78 GB Fasting
4 Nausea −/+ 1 × 14 16.0 36 117 GB Antibiotics
5 +/− 1 × 9 (1× 8, 1 × 5, 1 × 11) 17.9 25 168 GB Antibiotics
6 Appetite loss +/+ 1 × 14 21.0 14 c GB Fasting, antibiotics
7 Vomiting −/− 2 × 2, 1 × 6 13.1 19 20 GB Fasting, UDCA
8 Epigastralgia +/+ 1 × 11 (1 × 14) 27.4 43 50 GB, CBD UDCA, antibiotics
9 Epigastralgia −/− 1 × 8 (1 × 3) 22.7 21 37 GB UDCA
10 −/− 1 × 7 18.7 8 39 GB
11 −/− 1 × 4 17.5 274 424 GB
  1. CTRX Ceftriaxone, CBD Common bile duct, GB Gall bladder, UDCA Ursodeoxycholic acid
  2. aFrom the initiation of CTRX
  3. bFrom the cessation of CTRX
  4. cThese patients died before their follow-up abdominal CT
\